Senti Biosciences Announces New Employment Inducement Grants
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/26/2026
- Wall Street ends higher as tech rebounds before Nvidia results
- Oil settles down more than 3%; investors shrug off US sanctions on Iran
- UBS says bull market has further to run
- S&P 500 may pull back before midterms, but Citi says buy the dip
- Global yield relief evaporates as U.S. rates push back toward multi-decade peaks
- Wall Street ends higher as tech rebounds before Nvidia results
- Six Flags to move headquarters from Charlotte to Arlington, Texas
- Boston Scientific discloses cybersecurity incident causing global disruption
- Intuit (INTU) Tops Q4 EPS; Offers FY27 Guidance
- Oppenheimer Upgrades Capricor Therapeutics (CAPR) to Outperform 'on Approval Optimism'
Senti Biosciences, Inc. (SNTI) PT Raised to $12 at Chardan Capital Markets
December 4, 2024 6:54 AM ESTChardan Capital Markets analyst Geulah Livshits raised the price target on Senti Biosciences, Inc. (NASDAQ: SNTI) to $12.00 (from $10.00) while maintaining a Buy rating.
The analyst comments "On 3 December, Senti Biosciences hosted a call to discuss initial data from the phase I trial of its... More
